Terms: = Brain cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Clinical Outcome
4 results:
1. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR;
J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296
[TBL] [Abstract] [Full Text] [Related]
2. NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis.
Liu MF; Jin T; Shen JH; Shen ZY; Zheng ZC; Zhang ZL; Xu LY; Li EM; Xu HX
J Neurooncol; 2011 Aug; 104(1):119-27. PubMed ID: 21184133
[TBL] [Abstract] [Full Text] [Related]
3. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.
Bax DA; Mackay A; Little SE; Carvalho D; Viana-Pereira M; Tamber N; Grigoriadis AE; Ashworth A; Reis RM; Ellison DW; Al-Sarraj S; Hargrave D; Jones C
Clin Cancer Res; 2010 Jul; 16(13):3368-77. PubMed ID: 20570930
[TBL] [Abstract] [Full Text] [Related]
4. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract] [Full Text] [Related]
